NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Asparaginase

Last Revision: July 20, 2020.

Estimated reading time: 1 minute

CASRN: 9015-68-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of asparaginase during breastfeeding. . Because aspariginase is a large protein molecule with a molecular weight of about 140,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, the manufacturer recommends that breastfeeding be discontinued during asparaginase therapy and for 3 months after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Asparaginase

CAS Registry Number

CASRN: 9015-68-3

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzymes

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...